[
  {
    "question": "35 years old presented with posterior thigh weakness and calf weakness and he can not do plantar weakness CK level X35 double normal, Dx?",
    "option_a": "Dysferlinopathy.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Dysferlinopathy is a group of autosomal recessive muscular dystrophies due to mutations in the dysferlin gene. It commonly presents in young adults with weakness predominantly affecting the calf muscles (as seen in Miyoshi myopathy) or the proximal limb muscles (limb\u2010girdle muscular dystrophy type 2B). Defective dysferlin impairs muscle membrane repair after injury, leading to progressive muscle fiber degeneration. The disease typically shows markedly elevated creatine kinase levels (often 10\u2013100 times the normal limit) due to ongoing muscle breakdown, as supported by recent molecular and pathological studies. Clinically, patients present in their 20s\u201330s with muscle weakness that may initially affect the posterior thigh and calf regions. Difficulty with activities requiring calf strength (such as plantar flexion, i.e. standing on tiptoe) is common. The high CK level is a biochemical marker reflecting muscle fiber damage. The diagnosis is based on a combination of clinical history, markedly elevated CK levels, electromyography (showing a myopathic pattern), and confirmation via genetic testing or muscle biopsy demonstrating dystrophic changes. Differential diagnoses include other limb\u2010girdle muscular dystrophies and inflammatory myopathies, which can be differentiated based on genetic studies and immunohistochemical staining. Management is primarily supportive. First-line recommendations include physical therapy, occupational therapy, and regular cardiopulmonary assessments. There is no curative treatment yet, although research in gene therapy is progressing. For pregnant or lactating patients, management remains supportive with close monitoring since medications used are generally non-teratogenic; however, any experimental therapies or interventions should be discussed with a maternal\u2013fetal medicine specialist. Option A (Dysferlinopathy) is correct. The presentation of posterior thigh and calf weakness with very high CK strongly suggests a muscular dystrophy, most consistent with a dysferlinopathy given the age and pattern of weakness. Other options (if present) would reflect different neuromuscular disorders that do not align as well with the CK elevation and distribution of muscle weakness. 1. Dysferlinopathies can present either as a distal (Miyoshi myopathy) or proximal (LGMD2B) muscle weakness, so careful clinical evaluation is necessary. 2. Markedly elevated serum CK levels (often >10 times normal) are a key laboratory clue. 3. Genetic testing is essential for definitive diagnosis. Recent studies have reinforced the role of dysferlin in membrane repair and have highlighted inflammatory changes in muscle biopsies that can mimic inflammatory myopathies. There is ongoing research into gene therapy approaches, though current management remains supportive.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "female with wt gain CTS in left side, had delayed reflex, what to do next:",
    "option_a": "TFT",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Carpal tunnel syndrome (CTS) involves compression of the median nerve at the wrist. In patients, especially females with weight gain, associated systemic conditions should be considered as contributing factors. Hypothyroidism leads to the deposition of mucopolysaccharides in soft tissues causing non-pitting edema. This edema can lead to increased pressure within the carpal tunnel, compressing the median nerve. Additionally, hypothyroidism is characterized by a slowing of reflexes, making delayed tendon reflexes a clinical clue. A female patient presenting with CTS, weight gain, and delayed reflexes raises clinical suspicion for hypothyroidism. The nerve compression symptoms are secondary to metabolic changes from thyroid hormone deficiency, linking systemic endocrine dysfunction to focal neuropathy. The evaluation includes a detailed history and physical exam with emphasis on thyroid function. The next step is to order thyroid function tests (TFTs) evaluating TSH and free T4 levels. Differential considerations include repetitive strain injury and diabetes-related neuropathy, but these lack the systemic features (e.g. weight gain, delayed reflexes) seen in hypothyroidism. First-line management of hypothyroidism involves thyroid hormone replacement (typically levothyroxine) with dose adjustments based on clinical response and laboratory values. In pregnant or lactating women, levothyroxine is the treatment of choice, with careful monitoring of thyroid levels and fetal well-being. It is essential to address the underlying endocrine disorder to alleviate the secondary compressive neuropathy. Option A (TFT) is correct because the patient\u2019s symptoms suggest hypothyroidism as the underlying cause of her CTS. Other options, if provided, may include direct nerve interventions which would neglect the systemic etiology. 1. Hypothyroidism is a common and reversible cause of carpal tunnel syndrome. 2. Delayed relaxation of deep tendon reflexes is a classic sign of hypothyroidism. 3. Always consider systemic causes when CTS is accompanied by unusual clinical findings such as weight gain. Recent guidelines emphasize screening for thyroid dysfunction in patients with bilateral or atypical CTS presentations. Studies support that treating hypothyroidism often results in improvement or resolution of CTS symptoms.",
    "exam_year": "2021",
    "exam_type": "Part II",
    "image_url": "page_7.png"
  },
  {
    "question": "pt with scapular winging and weakness, he has very high CK, Muscle Bx showed Esinophils:",
    "option_a": "Calpinopathy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Calpainopathy (LGMD type 2A) is a limb\u2010girdle muscular dystrophy characterized by mutations in the CAPN3 gene encoding calpain-3, a muscle-specific protease. It predominantly causes proximal muscle weakness and may involve scapular winging. Mutations in the CAPN3 gene result in a deficiency of calpain-3, interfering with normal muscle protein turnover and repair. On muscle biopsy, characteristic dystrophic changes may be seen. Notably, inflammatory infiltrates \u2013 sometimes including eosinophils \u2013 can be present, which may confound the diagnosis by mimicking an inflammatory myopathy. Patients often present with progressive limb weakness, particularly affecting the shoulder girdle leading to scapular winging, and may exhibit very high creatine kinase levels due to ongoing muscle damage. The presence of eosinophils on biopsy, although not universally seen, is a recognized finding in some cases of calpainopathy. Diagnosis involves clinical evaluation, serum CK measurement, electromyography, and ultimately, muscle biopsy. Genetic testing for CAPN3 mutations confirms the diagnosis. Differential diagnoses include other forms of limb\u2010girdle muscular dystrophy, polymyositis, and other inflammatory myopathies; the pattern of weakness, age at onset, and genetic confirmation help to differentiate these conditions. Management is currently supportive and includes physical therapy, occupational therapy, and sometimes orthopedic interventions for contractures or mobility assistance. There is no approved disease-modifying therapy at present. In pregnant or lactating patients, management remains supportive with careful monitoring as no specific pharmacological therapy is indicated; precautions simply involve avoiding excessive stress on weakened musculature and ensuring close follow-up. Option A (Calpainopathy) is correct. The combination of scapular winging, high CK levels, and muscle biopsy findings featuring eosinophils aligns with calpainopathy (LGMD2A). Other conditions would either not show this constellation of biopsy findings or would have different clinical presentations. 1. In calpainopathy, inflammatory cells including eosinophils on muscle biopsy can mimic an inflammatory myositis. 2. Scapular winging is a common clue pointing toward a muscular dystrophy affecting proximal muscles. 3. Genetic testing is essential for definitive classification of limb\u2010girdle muscular dystrophies. Recent studies have underscored the variability in histopathological findings in calpainopathy, including the occasional presence of eosinophils, which can lead to misdiagnosis. Ongoing research is evaluating potential gene-based therapies, but current treatment remains rehabilitative and supportive.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "2 months old had apnea macriglossia and cardiac disease, Dx:",
    "option_a": "Pompe Disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Pompe disease, or glycogen storage disease type II, is a lysosomal storage disorder caused by a deficiency of acid alpha-glucosidase. The classic infantile form presents within the first few months of life and is characterized by cardiac, respiratory, and skeletal muscle involvement. The enzyme deficiency leads to accumulation of glycogen in lysosomes, particularly in cardiac and skeletal muscles. This glycogen build-up causes muscle fiber damage, resulting in hypertrophic cardiomyopathy, generalized hypotonia, and respiratory difficulties. Although macroglossia is more classically associated with conditions like hypothyroidism or certain overgrowth syndromes, it can also be observed in Pompe disease due to oropharyngeal muscle involvement. An infant presenting at 2 months of age with apnea (reflecting respiratory muscle involvement), cardiac disease (typically hypertrophic cardiomyopathy), and macroglossia fits well with the infantile presentation of Pompe disease. These signs support a diagnosis of a systemic metabolic myopathy. Diagnosis is based on clinical presentation, markedly elevated CK levels, and definitive enzyme assay for acid alpha-glucosidase activity. Genetic testing can confirm the mutation in the GAA gene. Differential diagnoses include other metabolic disorders (such as other glycogen storage diseases) and congenital hypothyroidism; however, the pronounced cardiac involvement strongly favors Pompe disease. The cornerstone of treatment for infantile Pompe disease is enzyme replacement therapy (ERT) with alglucosidase alfa, which has been shown to improve survival and cardiac function. Supportive care includes respiratory support and nutritional management. In pregnant or lactating patients with a known history, a multidisciplinary approach is essential. Although data on ERT in pregnancy are limited, treatment decisions should be individualized by weighing the benefits against potential risks, with input from maternal\u2013fetal medicine specialists. Option A (Pompe Disease) is correct because the constellation of apnea, cardiac involvement, and features like macroglossia in a 2\u2010month\u2010old infant strongly supports the diagnosis of infantile Pompe disease. Alternatives would not typically show this combination of severe cardiac and muscular findings at such an early age. 1. Infantile Pompe disease is marked by hypertrophic cardiomyopathy and profound muscle weakness, often presenting within the first few months of life. 2. Early diagnosis and initiation of enzyme replacement therapy are critical to improving outcomes. 3. Although macroglossia is more commonly associated with other conditions, in the context of Pompe, it underscores generalized muscle involvement. Recent guidelines and studies have shown that early initiation of ERT in Pompe disease leads to improved cardiac outcomes and motor development. Ongoing research is evaluating adjunctive therapies and long-term outcomes in treated patients, with an emphasis on optimizing care protocols in special populations including pregnant or lactating mothers when relevant.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with hx of multineuropathy multiplex, Bx showed necrosis and inflammatory cells in the vessels. What is the Dx?",
    "option_a": "Vasculitic neuropathy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Vasculitic neuropathy is a disorder in which an immune-mediated inflammation affects the blood vessels supplying the nerves. This leads to multifocal ischemic injury and segmental nerve fiber loss, often presenting as mononeuritis multiplex (asymmetric, patchy involvement of peripheral nerves). The disease mechanism involves an inflammatory attack on the vasa nervorum, resulting in fibrinoid necrosis and infiltrates of inflammatory cells in the vessel wall. This vascular inflammation compromises blood flow, causing ischemia and subsequent nerve injury. It is commonly associated with systemic vasculitides such as polyarteritis nodosa or rheumatoid vasculitis, as well as non-systemic vasculitic neuropathy in some cases. Patients typically present with sudden-onset, asymmetric, painful sensory and motor deficits in different nerve territories. The hallmark is mononeuritis multiplex, and a nerve biopsy revealing vessel necrosis with inflammatory infiltrates confirms the diagnosis, linking the clinical picture to an underlying vasculitic process. The workup includes detailed history and physical examination, nerve conduction studies showing axonal damage, laboratory evaluations for systemic inflammation (e.g., ESR, CRP, ANCA), and definitive tissue biopsy. Differential diagnoses include diabetic neuropathy, amyloid neuropathy, and chronic inflammatory demyelinating polyneuropathy (CIDP), which can be distinguished by the pattern of nerve involvement and additional systemic findings. The first-line treatment is immunosuppression, most commonly high-dose corticosteroids. If there is an inadequate response or in severe cases, additional immunosuppressive agents (e.g., cyclophosphamide or methotrexate) are added. In pregnant or lactating patients, the use of corticosteroids might be acceptable at the lowest effective doses; other immunosuppressants require a careful risk\u2013benefit analysis with consultation of up-to-date obstetrical guidelines. Option A is correct because the biopsy findings of necrosis and inflammatory cells in the vessels are pathognomonic for vasculitic neuropathy. The other options are not presented in this question. 1. Mononeuritis multiplex is a red flag for an underlying vasculitis. 2. Nerve biopsy is the gold standard for diagnosis. 3. Early immunosuppressive treatment can prevent irreversible nerve damage. Recent guidelines emphasize early, aggressive immunosuppression to limit nerve damage, with ongoing research into steroid-sparing agents, especially in populations like pregnant women, where drug safety is a major concern.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario typical for paramyotonia congenita; asked about the gene?",
    "option_a": "Na channel",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Paramyotonia congenita is a non-dystrophic myotonic disorder characterized by episodes of muscle stiffness that are particularly sensitive to cold exposure. It is a classic example of a channelopathy affecting skeletal muscle. The disorder is caused by autosomal dominant mutations in the SCN4A gene, which encodes the voltage-gated sodium channel in skeletal muscle. These mutations alter the channel\u2019s inactivation kinetics, leading to abnormal muscle excitability and delayed relaxation (myotonia), especially when triggered by cold temperatures. Clinically, patients experience stiffness and difficulty relaxing muscles following contraction. Unlike classical myotonia congenita, which may exhibit a warm-up phenomenon (improvement with repeated contractions), symptoms in paramyotonia congenita typically worsen with repeated activity and cold exposure. This makes everyday activities and exposure to cold, such as eating ice cream or being in a cold environment, particularly troublesome. Diagnosis is made based on the clinical history of cold-induced myotonia and confirmed by genetic testing for mutations in the SCN4A gene. Differential diagnoses include myotonia congenita (which demonstrates a warm-up phenomenon) and myotonic dystrophy (accompanied by multisystem manifestations like cataracts and cardiac conduction defects). The management centers on lifestyle modification such as avoiding cold exposure, which is the primary trigger. Pharmacologic therapy may include mexiletine, a sodium channel blocker, which has been found effective in reducing myotonia. In the context of pregnancy or lactation, non-pharmacological management is preferred, but if medication is essential, the risks, benefits, and available safety data should be thoroughly discussed. Option A (Na channel) is correct because mutations affecting the sodium channel (SCN4A) are the underlying cause of paramyotonia congenita. Other options are not provided, making this choice the only and appropriate answer. 1. Cold exposure is a key trigger in paramyotonia congenita. 2. Unlike myotonia congenita, repeated muscle activity does not improve symptoms. 3. Genetic testing for SCN4A mutations is diagnostic. Recent studies support the use of mexiletine as an effective treatment. There is also increasing emphasis on genetic counseling and personalized management strategies, particularly when dealing with patients of reproductive age.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "What is the medication cause neuropathy and myopathy?",
    "option_a": "Dapson",
    "option_b": "Chloroquine",
    "option_c": "Hydralazine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Certain medications can cause both neuropathy and myopathy due to their toxic effects on peripheral nerves and muscle fibers. Recognizing drug-induced neuromyopathy is essential in patients with unexplained neuromuscular symptoms. Chloroquine (and its derivative hydroxychloroquine) can accumulate in muscle tissue and disrupt lysosomal function, leading to the formation of autophagic vacuoles. This results in a vacuolar myopathy, and in some cases, peripheral neuropathic changes may also occur. Patients on long-term chloroquine therapy might present with proximal muscle weakness and myalgia. Although pure neuropathy is less common, some patients may exhibit both muscle weakness and sensory changes. The clinical picture can mimic other myopathies, making a careful drug history crucial. The evaluation includes a detailed medication history, laboratory tests (such as creatine kinase levels), electromyography (EMG) studies, and, if necessary, muscle biopsy to confirm the presence of vacuolar changes. Differential diagnoses include statin-induced myopathy, idiopathic inflammatory myopathies, and diabetic neuropathy. The primary treatment is the discontinuation of the offending agent, i.e., chloroquine. Supportive treatments such as physical therapy may aid recovery. In pregnant or lactating patients, alternative medications with safer profiles should be considered, and if the patient is being treated for a condition like malaria or autoimmune disease, the risk\u2013benefit ratio of continuing chloroquine must be carefully evaluated according to current obstetrical guidelines. Option B (Chloroquine) is correct. Dapsone (Option A) is more commonly associated with hemolytic anemia and methemoglobinemia, and Hydralazine (Option C) is typically linked to drug-induced lupus rather than direct neuromyopathy. 1. Always review medication history in new-onset neuromuscular complaints. 2. Chloroquine toxicity typically manifests as a vacuolar myopathy with or without neuropathy. 3. Early recognition and discontinuation of the drug can lead to symptom improvement. Current research highlights the mechanism of chloroquine-induced muscle toxicity and underscores the importance of monitoring patients on long-term therapy. Recent guidelines recommend regular neuromuscular assessments in such patients and call for cautious use in women who are pregnant or breastfeeding.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Young male patient came with eyelid myotonia increased after eating icecream or exposed to cold; what is the Dx?",
    "option_a": "Paramyotonia congenita",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Paramyotonia congenita is a myotonic disorder primarily characterized by muscle stiffness that worsens with cold exposure, in contrast to other myotonic conditions which may improve with activity (warm-up phenomenon). The condition is due to mutations in the SCN4A gene encoding the voltage-gated sodium channel in skeletal muscle. These mutations cause abnormal channel behavior, leading to prolonged muscle contraction (myotonia) when triggered by cold exposure. The classic clinical presentation involves symptoms such as eyelid myotonia (delayed relaxation after contraction), which is exacerbated by cold stimuli such as eating ice cream or exposure to a cold environment. This presentation distinguishes it from other myotonic disorders that have associated systemic features or a warm-up phenomenon. Diagnosis is based on the clinical history and examination, supported by genetic testing confirming SCN4A mutations. Differential diagnoses include myotonic dystrophy (which presents with multisystem involvement including cataracts, frontal balding, and cardiac conduction defects) and myotonia congenita (which typically improves with repeated contractions). Management primarily involves lifestyle modifications including avoidance of cold exposure and triggers. Pharmacologically, mexiletine, a sodium channel blocker, is used to reduce myotonia. For pregnant or lactating women, non-pharmacologic management is preferred; if treatment is necessary, any medication use should be balanced with the potential risk to the fetus or infant according to current safety data and guidelines. Option A (Paramyotonia congenita) is correct because the described cold-induced eyelid myotonia is a hallmark of this condition. Other options were not provided, making this the appropriate answer. 1. Cold is a potent trigger in paramyotonia congenita, worsening myotonic symptoms. 2. Genetic testing for SCN4A mutations is diagnostic. 3. Differentiation from myotonic dystrophy is essential due to the absence of systemic features in paramyotonia congenita. Recent publications reinforce the utility of mexiletine in managing symptoms and emphasize the role of non-pharmacologic strategies. Ongoing clinical trials continue to explore safer treatment modalities, particularly in the context of pregnancy and lactation where drug safety is paramount.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Old patient came with sensory motor neuropathy with distal weakness (he has dorsiflexion weakness), weight loss, and malaise; what is the next step:",
    "option_a": "CT chest",
    "option_b": "send for Anti Hu",
    "option_c": "Electrophoresis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "In older patients presenting with a subacute sensory\u2010motor neuropathy, especially with distal involvement (such as dorsiflexion weakness) accompanied by systemic features like weight loss and malaise, it is important to consider a paraneoplastic etiology. Paraneoplastic neuropathies are immune\u2010mediated responses triggered by an underlying malignancy, most often small cell lung cancer. Paraneoplastic neuropathies occur when tumor antigens (commonly from small cell lung cancer) induce an immune response that cross-reacts with components of the peripheral nervous system. Anti\u2010Hu antibodies are frequently implicated. Although testing for these antibodies (option B) is useful for confirmation, initial evaluation should identify the source of the malignancy. CT imaging of the chest is preferred to detect occult masses responsible for the paraneoplastic syndrome. The presentation of distal weakness (e.g., dorsiflexion weakness), sensory deficits, weight loss, and malaise in an elderly patient strongly suggests an underlying neoplasm driving the neuropathy. Identifying the lung mass not only confirms the paraneoplastic nature but also directs oncologic management, which may improve neurologic outcomes. The differential diagnosis includes diabetic neuropathy, toxic exposures, amyloid neuropathy, and paraneoplastic neuropathy. In this context, imaging (CT chest) is the first step to detect a potential lung primary. Anti\u2010Hu antibody testing may be employed afterwards to support the diagnosis, and nerve conduction studies can document the neuropathy pattern. First-line management involves prompt identification and treatment of the underlying malignancy, typically via CT chest scanning. Once the tumor is identified, oncologic treatment (chemotherapy, radiotherapy, or surgery) is instituted. Immunomodulatory treatments (e.g., IV immunoglobulin, plasmapheresis) may be considered later if neurological deficits persist. In patients who are pregnant or lactating, imaging studies like CT must be judiciously used after weighing the risks and benefits, with appropriate shielding or alternative imaging (e.g., MRI without gadolinium) considered if possible. Option A (CT chest) is the appropriate first step because it directly seeks the occult malignancy responsible for a paraneoplastic process. Option B (send for Anti Hu) is confirmatory but not the initial investigation, while Option C (Electrophoresis) is used for conditions like paraproteinemic neuropathies rather than a paraneoplastic syndrome. 1. In older patients with neuropathy and weight loss, always consider an occult malignancy as a potential trigger. 2. Paraneoplastic neuropathies are often associated with anti\u2010Hu antibodies, but imaging should precede antibody testing to rapidly localize the primary tumor. 3. Early identification of the tumor can be crucial for both oncologic and neurological management. Recent guidelines emphasize early tumor detection via CT chest in suspected paraneoplastic syndromes, with antibody testing serving as a secondary marker. Studies continue to support that prompt treatment of the underlying malignancy can stabilize or improve neurological outcomes.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with channelopathy what is the best work up:",
    "option_a": "long exercise test",
    "option_b": "Short exercise test",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "In older patients presenting with a subacute sensory\u2010motor neuropathy, especially with distal involvement (such as dorsiflexion weakness) accompanied by systemic features like weight loss and malaise, it is important to consider a paraneoplastic etiology. Paraneoplastic neuropathies are immune\u2010mediated responses triggered by an underlying malignancy, most often small cell lung cancer. Paraneoplastic neuropathies occur when tumor antigens (commonly from small cell lung cancer) induce an immune response that cross-reacts with components of the peripheral nervous system. Anti\u2010Hu antibodies are frequently implicated. Although testing for these antibodies (option B) is useful for confirmation, initial evaluation should identify the source of the malignancy. CT imaging of the chest is preferred to detect occult masses responsible for the paraneoplastic syndrome. The presentation of distal weakness (e.g., dorsiflexion weakness), sensory deficits, weight loss, and malaise in an elderly patient strongly suggests an underlying neoplasm driving the neuropathy. Identifying the lung mass not only confirms the paraneoplastic nature but also directs oncologic management, which may improve neurologic outcomes. The differential diagnosis includes diabetic neuropathy, toxic exposures, amyloid neuropathy, and paraneoplastic neuropathy. In this context, imaging (CT chest) is the first step to detect a potential lung primary. Anti\u2010Hu antibody testing may be employed afterwards to support the diagnosis, and nerve conduction studies can document the neuropathy pattern. First-line management involves prompt identification and treatment of the underlying malignancy, typically via CT chest scanning. Once the tumor is identified, oncologic treatment (chemotherapy, radiotherapy, or surgery) is instituted. Immunomodulatory treatments (e.g., IV immunoglobulin, plasmapheresis) may be considered later if neurological deficits persist. In patients who are pregnant or lactating, imaging studies like CT must be judiciously used after weighing the risks and benefits, with appropriate shielding or alternative imaging (e.g., MRI without gadolinium) considered if possible. Option A (CT chest) is the appropriate first step because it directly seeks the occult malignancy responsible for a paraneoplastic process. Option B (send for Anti Hu) is confirmatory but not the initial investigation, while Option C (Electrophoresis) is used for conditions like paraproteinemic neuropathies rather than a paraneoplastic syndrome. 1. In older patients with neuropathy and weight loss, always consider an occult malignancy as a potential trigger. 2. Paraneoplastic neuropathies are often associated with anti\u2010Hu antibodies, but imaging should precede antibody testing to rapidly localize the primary tumor. 3. Early identification of the tumor can be crucial for both oncologic and neurological management. Recent guidelines emphasize early tumor detection via CT chest in suspected paraneoplastic syndromes, with antibody testing serving as a secondary marker. Studies continue to support that prompt treatment of the underlying malignancy can stabilize or improve neurological outcomes.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "GBS scenario, asking what is the predicting factor for intubation?",
    "option_a": "presence of dysautonomia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "In older patients presenting with a subacute sensory\u2010motor neuropathy, especially with distal involvement (such as dorsiflexion weakness) accompanied by systemic features like weight loss and malaise, it is important to consider a paraneoplastic etiology. Paraneoplastic neuropathies are immune\u2010mediated responses triggered by an underlying malignancy, most often small cell lung cancer. Paraneoplastic neuropathies occur when tumor antigens (commonly from small cell lung cancer) induce an immune response that cross-reacts with components of the peripheral nervous system. Anti\u2010Hu antibodies are frequently implicated. Although testing for these antibodies (option B) is useful for confirmation, initial evaluation should identify the source of the malignancy. CT imaging of the chest is preferred to detect occult masses responsible for the paraneoplastic syndrome. The presentation of distal weakness (e.g., dorsiflexion weakness), sensory deficits, weight loss, and malaise in an elderly patient strongly suggests an underlying neoplasm driving the neuropathy. Identifying the lung mass not only confirms the paraneoplastic nature but also directs oncologic management, which may improve neurologic outcomes. The differential diagnosis includes diabetic neuropathy, toxic exposures, amyloid neuropathy, and paraneoplastic neuropathy. In this context, imaging (CT chest) is the first step to detect a potential lung primary. Anti\u2010Hu antibody testing may be employed afterwards to support the diagnosis, and nerve conduction studies can document the neuropathy pattern. First-line management involves prompt identification and treatment of the underlying malignancy, typically via CT chest scanning. Once the tumor is identified, oncologic treatment (chemotherapy, radiotherapy, or surgery) is instituted. Immunomodulatory treatments (e.g., IV immunoglobulin, plasmapheresis) may be considered later if neurological deficits persist. In patients who are pregnant or lactating, imaging studies like CT must be judiciously used after weighing the risks and benefits, with appropriate shielding or alternative imaging (e.g., MRI without gadolinium) considered if possible. Option A (CT chest) is the appropriate first step because it directly seeks the occult malignancy responsible for a paraneoplastic process. Option B (send for Anti Hu) is confirmatory but not the initial investigation, while Option C (Electrophoresis) is used for conditions like paraproteinemic neuropathies rather than a paraneoplastic syndrome. 1. In older patients with neuropathy and weight loss, always consider an occult malignancy as a potential trigger. 2. Paraneoplastic neuropathies are often associated with anti\u2010Hu antibodies, but imaging should precede antibody testing to rapidly localize the primary tumor. 3. Early identification of the tumor can be crucial for both oncologic and neurological management. Recent guidelines emphasize early tumor detection via CT chest in suspected paraneoplastic syndromes, with antibody testing serving as a secondary marker. Studies continue to support that prompt treatment of the underlying malignancy can stabilize or improve neurological outcomes.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with leber optic neuropathy; what is your next step:",
    "option_a": "ECG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "In older patients presenting with a subacute sensory\u2010motor neuropathy, especially with distal involvement (such as dorsiflexion weakness) accompanied by systemic features like weight loss and malaise, it is important to consider a paraneoplastic etiology. Paraneoplastic neuropathies are immune\u2010mediated responses triggered by an underlying malignancy, most often small cell lung cancer. Paraneoplastic neuropathies occur when tumor antigens (commonly from small cell lung cancer) induce an immune response that cross-reacts with components of the peripheral nervous system. Anti\u2010Hu antibodies are frequently implicated. Although testing for these antibodies (option B) is useful for confirmation, initial evaluation should identify the source of the malignancy. CT imaging of the chest is preferred to detect occult masses responsible for the paraneoplastic syndrome. The presentation of distal weakness (e.g., dorsiflexion weakness), sensory deficits, weight loss, and malaise in an elderly patient strongly suggests an underlying neoplasm driving the neuropathy. Identifying the lung mass not only confirms the paraneoplastic nature but also directs oncologic management, which may improve neurologic outcomes. The differential diagnosis includes diabetic neuropathy, toxic exposures, amyloid neuropathy, and paraneoplastic neuropathy. In this context, imaging (CT chest) is the first step to detect a potential lung primary. Anti\u2010Hu antibody testing may be employed afterwards to support the diagnosis, and nerve conduction studies can document the neuropathy pattern. First-line management involves prompt identification and treatment of the underlying malignancy, typically via CT chest scanning. Once the tumor is identified, oncologic treatment (chemotherapy, radiotherapy, or surgery) is instituted. Immunomodulatory treatments (e.g., IV immunoglobulin, plasmapheresis) may be considered later if neurological deficits persist. In patients who are pregnant or lactating, imaging studies like CT must be judiciously used after weighing the risks and benefits, with appropriate shielding or alternative imaging (e.g., MRI without gadolinium) considered if possible. Option A (CT chest) is the appropriate first step because it directly seeks the occult malignancy responsible for a paraneoplastic process. Option B (send for Anti Hu) is confirmatory but not the initial investigation, while Option C (Electrophoresis) is used for conditions like paraproteinemic neuropathies rather than a paraneoplastic syndrome. 1. In older patients with neuropathy and weight loss, always consider an occult malignancy as a potential trigger. 2. Paraneoplastic neuropathies are often associated with anti\u2010Hu antibodies, but imaging should precede antibody testing to rapidly localize the primary tumor. 3. Early identification of the tumor can be crucial for both oncologic and neurological management. Recent guidelines emphasize early tumor detection via CT chest in suspected paraneoplastic syndromes, with antibody testing serving as a secondary marker. Studies continue to support that prompt treatment of the underlying malignancy can stabilize or improve neurological outcomes.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Typcial scenario of MELAS and asking how to make the Dx?",
    "option_a": "lactate pyruvate profile.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) is a mitochondrial disorder that typically presents with multifocal neurologic deficits, seizures, and muscle involvement. A key diagnostic feature is biochemical evidence of abnormal mitochondrial metabolism, which is often assessed by measuring the lactate-to-pyruvate ratio. The disorder is most frequently caused by a point mutation in mitochondrial DNA (most notably the A3243G mutation in the MT-TL1 gene), leading to impaired oxidative phosphorylation. This defect results in energy failure in high-demand tissues and accumulation of lactic acid, which explains the lactic acidosis seen in these patients. Clinically, patients with MELAS present with stroke\u2010like episodes that do not conform to typical vascular territories, seizures, and progressive neurodegeneration. The accumulation of lactate systemically correlates with the muscle weakness and neurological decline observed in this condition. Initial evaluation includes measurement of serum and CSF lactate and pyruvate levels (with an elevated lactate/pyruvate ratio supporting the diagnosis). Neuroimaging such as MRI may reveal stroke\u2010like lesions. More definitive investigations include muscle biopsy (showing ragged red fibers) and molecular genetic testing for mitochondrial mutations. Differential diagnoses to consider include other mitochondrial cytopathies and vascular causes of stroke. There is no definitive cure for MELAS; management is largely supportive. Acute stroke-like episodes may be managed with arginine supplementation, and various antioxidant therapies (e.g., coenzyme Q10, L-carnitine) have been used, although evidence remains limited. In the context of pregnancy or lactation, careful selection of supportive therapies is needed to avoid mitochondrial toxins and ensure fetal/maternal safety, with multidisciplinary management recommended. Option A (lactate pyruvate profile) is the appropriate and initial diagnostic test to screen for MELAS by revealing lactic acidosis and an abnormal lactate/pyruvate ratio. The marked option B is not supported by the standard diagnostic approach for MELAS, making option A the correct answer. 1. The acronym MELAS reminds clinicians of its key features: Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like episodes. 2. A lactate pyruvate profile is a quick and useful screening tool in patients with suspected mitochondrial disorders. Recent reviews emphasize a combination of biochemical, radiological, and genetic testing to improve diagnostic accuracy in MELAS. Although genetic testing is becoming more accessible, the lactate/pyruvate profile remains a frontline investigation per updated mitochondrial disease guidelines.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with Hypokalemic periodic paralysis; K=2.6, after you give potassium to the patient what is the treatment?",
    "option_a": "daily potassium supplement",
    "option_b": "Acetazolamide",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Hypokalemic periodic paralysis is a channelopathy resulting in episodes of muscle weakness associated with low serum potassium levels. After acute correction of hypokalemia, prophylactic treatment is aimed at reducing the frequency of future episodes. This condition is typically due to inherited mutations in ion channels (calcium or sodium channels), which disrupt normal muscle membrane excitability. Acetazolamide, a carbonic anhydrase inhibitor, can induce a mild metabolic acidosis that stabilizes these channels and reduces the frequency and severity of attacks. Patients often present with episodic muscle weakness that may be triggered by factors such as high carbohydrate meals, stress, or rest after exercise. The laboratory finding of marked hypokalemia during an attack supports the diagnosis. Diagnosis is confirmed by serum potassium measurements during attacks, family history evaluation, and, if indicated, genetic testing. Differential diagnoses include thyrotoxic periodic paralysis (which is more common in the context of hyperthyroidism), as well as other metabolic or neuromuscular disorders. Acute management involves potassium replacement to correct the hypokalemia. For long-term prevention of attacks, acetazolamide (Option B) is typically considered first-line therapy. Daily potassium supplementation (Option A) is not generally favored for prophylaxis because of variable absorption and potential risk of rebound fluctuations. In pregnancy and lactation, the use of acetazolamide requires careful evaluation; while it is often avoided due to potential fetal risks (typically classified as a Category C drug), it may be used when the benefits outweigh the risks under close monitoring. Option B (Acetazolamide) is correct as it is well supported by clinical evidence and guideline recommendations for prophylaxis in hypokalemic periodic paralysis. Option A (daily potassium supplement) may be used in acute management but is not the preferred long-term strategy. 1. Recognize that episodes are often precipitated by carbohydrate-rich meals. 2. Acetazolamide has a well-established role in reducing attack frequency in hypokalemic periodic paralysis. Recent clinical studies reinforce the efficacy of acetazolamide in prophylaxis for hypokalemic periodic paralysis, and guidelines continue to support its use. Ongoing research is focused on understanding ion channel mutations to further refine treatment options.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient diagnosed with ALS, his son ask you not to tell his father about the diagnosis?",
    "option_a": "tell the son that his father has the right to know about his condition.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The ethical principle of patient autonomy mandates that a competent patient has the right to be informed about their own medical diagnosis, including serious conditions such as ALS (Amyotrophic Lateral Sclerosis). ALS is a progressive neurodegenerative disease characterized by the loss of both upper and lower motor neurons, leading to progressive muscle weakness, atrophy, and eventual respiratory failure. Clinically, patients exhibit symptoms of muscle weakness, fasciculations, spasticity, and dysphagia. The progressive nature of the disease necessitates early and honest communication to facilitate planning and palliative care. ALS is diagnosed based on clinical findings, supported by electromyography (EMG) studies and the El Escorial diagnostic criteria. Differential diagnoses include primary lateral sclerosis, multifocal motor neuropathy, and other neuromuscular disorders. Treatment is mainly palliative, with medications like riluzole and edaravone used to slow progression. Early disclosure of the diagnosis is critical for initiating multidisciplinary care, advanced directives, and psychological support. When considering pregnancy or lactation, treatment options such as riluzole require a careful assessment of risks versus benefits due to limited safety data. Option A is correct because it upholds the patient\u2019s right to know his diagnosis. Ethically, withholding such significant information from the patient violates the principle of autonomy, even if requested by a family member. 1. In ALS, timely and compassionate disclosure helps patients and families prepare for the disease progression. 2. Multidisciplinary care is essential in managing both the physical and psychological impacts of ALS. Current ethical guidelines from bodies such as the AMA emphasize full and honest disclosure of diagnoses to competent patients. Recent ALS research continues to highlight the importance of early supportive interventions to maximize quality of life.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Typcial scenario of MELAS and asking how to make the Dx?",
    "option_a": "lactate pyruvate profile.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This MCQ, identical to MCQ 99992585, focuses on the appropriate diagnostic workup for MELAS. The central concept is the importance of evaluating lactate and pyruvate levels as part of the initial biochemical screening for mitochondrial disorders. MELAS is caused by mitochondrial DNA mutations that impair oxidative phosphorylation, resulting in energy deficits and an accumulation of lactate. The lactate-to-pyruvate ratio is particularly useful in highlighting mitochondrial dysfunction. Patients typically experience stroke-like episodes, seizures, and general muscle weakness. Laboratory findings of elevated lactate \u2013 both systemically and in the CSF \u2013 support the clinical suspicion of MELAS. The workup for MELAS includes metabolic testing (serum lactate and pyruvate levels), neuroimaging (MRI showing stroke-like lesions), muscle biopsy, and genetic testing to confirm mutations (such as A3243G). Differential diagnoses include other mitochondrial disorders and atypical stroke etiologies. Management of MELAS is largely supportive, with strategies including arginine supplementation during acute episodes and the use of antioxidants like coenzyme Q10 and L-carnitine. In pregnant or lactating patients, treatment is tailored to maximize maternal benefit while minimizing risks to the fetus or infant. Option A (lactate pyruvate profile) is the correct initial diagnostic tool. The marked answer (B) does not reflect the standard approach. Therefore, option A is the appropriate choice. 1. A high lactate level is a hallmark of mitochondrial dysfunction in MELAS. 2. Stroke-like episodes in MELAS do not follow typical vascular distributions, which can aid in differentiating it from conventional strokes. Recent publications endorse the use of a combined biochemical (lactate/pyruvate measurement), imaging, and genetic approach for the diagnosis of MELAS. Advances in genetic testing continue to refine diagnostic accuracy and help tailor supportive treatment strategies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Same patient asking about the Ab?",
    "option_a": "anti GM1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The anti-GM1 antibody is most commonly associated with immune\u2010mediated neuropathies, especially Multifocal Motor Neuropathy (MMN). These antibodies (typically IgM) target the ganglioside GM1 present in the peripheral nerve membranes. In conditions such as MMN, anti-GM1 antibodies bind to nerve membranes, potentially interfering with sodium channel function and contributing to conduction block in motor nerves. This immune-mediated attack leads to focal demyelination without significant sensory involvement. Patients typically present with asymmetric, predominantly distal limb weakness (often affecting the upper extremities) with relative sparing of sensory function. The presence of anti-GM1 antibodies supports the diagnosis and helps differentiate MMN from other neuropathies. The diagnosis is made by clinical assessment, supported by nerve conduction studies showing multifocal conduction block and serologic testing for anti\u2010GM1 antibodies. Differential diagnoses include Guillain\u2013Barr\u00e9 syndrome variants and other chronic inflammatory neuropathies, but the isolated motor involvement is key. First-line management for MMN involves intravenous immunoglobulin (IVIG), which has been shown to improve muscle strength and function. Second-line options or immunosuppressants may be considered in refractory cases. In pregnancy and lactation, IVIG is considered relatively safe, but any immunomodulatory therapy should be managed in consultation with specialists. Option A, anti-GM1, is correct because it is the characteristic antibody found in patients with MMN. Other options (B, C, D) are not provided, but none would be as specific given the scenario described. \u2022 Anti-GM1 antibodies are a hallmark of MMN. \u2022 MMN typically presents with asymmetrical, pure motor weakness with conduction block on electrophysiological studies. \u2022 Early diagnosis is essential as IVIG can significantly improve outcomes. Recent studies and guidelines continue to support the use of IVIG in patients with MMN, with the presence of anti-GM1 antibodies being an important factor in confirming the diagnosis. Ongoing research is further clarifying the immunopathogenic mechanisms behind antibody-mediated nerve injury.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with hx of multineuropathy multiplex, Bx showed necrosis and inflammatory cells in the vessels. What is the Dx?",
    "option_a": "Vasculitic neuropathy",
    "option_b": "Mononeuritis multiplex",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Vasculitic neuropathy is a manifestation of systemic or isolated vasculitis affecting the vasa nervorum. It typically presents with a multifocal neuropathy pattern due to inflammation-induced ischemia in the peripheral nerves. The underlying mechanism involves necrotizing inflammation of small vessels that supply peripheral nerves. The immune-mediated attack leads to vessel wall destruction, resulting in ischemia and subsequent axonal injury in the nerves. Patients can present with episodes of mononeuritis multiplex \u2013 meaning multiple, asymmetric nerve deficits that evolve over time. The biopsy showing necrosis and inflammatory cells is a key diagnostic feature of vasculitic involvement. Diagnosis is based on clinical presentation (stepwise, multifocal deficits), supported by nerve biopsy findings. Differential diagnoses include diabetic neuropathy, amyloid neuropathy, and other causes of mononeuritis multiplex; however, the biopsy findings of vessel necrosis and inflammatory infiltrates are characteristic for vasculitis. First-line therapy involves high-dose corticosteroids to reduce inflammation. In cases of more severe or refractory disease, additional immunosuppressive agents (e.g., cyclophosphamide, azathioprine) may be used. In pregnancy and lactation, corticosteroids are generally considered safe at appropriate doses, but other immunosuppressants require careful risk\u2013benefit analysis and specialist consultation. Option A (Vasculitic neuropathy) is correct because the histopathological findings (necrosis and inflammatory cells in the vessel walls) are typical of vasculitis. Option B, 'Mononeuritis multiplex', describes the clinical pattern but is not a specific diagnosis; vasculitic neuropathy is one of the primary causes of mononeuritis multiplex. \u2022 A nerve biopsy is essential to confirm a diagnosis of vasculitic neuropathy. \u2022 Early aggressive immunosuppressive treatment can be crucial in preventing irreversible nerve damage. \u2022 Always differentiate descriptive clinical syndromes (like mononeuritis multiplex) from underlying etiologies. Current guidelines advocate for prompt immunosuppressive therapy in confirmed vasculitic neuropathy to halt progression. Recent research has refined the risk stratification and management algorithms, emphasizing the balance between therapeutic efficacy and potential adverse effects, especially in special populations such as pregnant women.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with right UL weakness and interinsic hand atrophy and diminished reflexes asking about Dx?",
    "option_a": "MMN",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Multifocal Motor Neuropathy (MMN) is an immune-mediated neuropathy characterized by purely motor deficits. It typically presents with asymmetric limb weakness, often affecting the upper limbs with a predilection for hand muscles. The pathology in MMN involves immune-mediated demyelination with conduction block along motor nerves. Anti-GM1 antibodies (often IgM) have been implicated in the disruption of nerve conduction, particularly in the distal segments of motor neurons. The patient\u2019s presentation of unilateral upper limb weakness, intrinsic hand muscle atrophy, and diminished reflexes is consistent with a lower motor neuron process. Unlike amyotrophic lateral sclerosis (ALS), which generally features both upper and lower motor neuron signs (with hyperreflexia due to UMN involvement), MMN is strictly motor and often shows reduced reflexes. Electrophysiological studies are crucial and typically demonstrate multifocal conduction block in motor nerves. The differential includes ALS, cervical radiculopathy, and other focal neuropathies. The absence of sensory loss and the presence of conduction block help in distinguishing MMN from conditions such as ALS (which also shows upper motor neuron features) and other neuropathies. The current first-line treatment for MMN is IVIG, which can lead to significant improvement in muscle strength. Second-line treatments such as cyclophosphamide or rituximab have been considered in refractory cases. In pregnancy and lactation, IVIG is generally safe, though careful monitoring is warranted when using any immunomodulatory therapy. Option A, MMN, is correct given the patient\u2019s clinical presentation. While ALS can present with hand atrophy, it generally shows both upper and lower motor neuron signs (e.g., hyperreflexia, spasticity) and typically follows a more rapid progression. The diminished reflexes in this patient support a diagnosis of MMN over ALS. \u2022 MMN frequently presents with asymmetric distal upper limb weakness without sensory involvement. \u2022 Electrophysiological studies revealing conduction block are key to diagnosis. \u2022 Early treatment with IVIG can improve functional outcomes. Recent clinical trials have reinforced the benefit of IVIG in MMN, and updated guidelines emphasize the importance of electrophysiological confirmation. Research continues into targeted immunotherapies, and the safety profile of IVIG in pregnancy supports its use in women of childbearing age when indicated.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Treatment of IBM?",
    "option_a": "Steroid",
    "option_b": "IVIG",
    "option_c": "Supportive treatment",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Inclusion Body Myositis (IBM) is an idiopathic inflammatory myopathy marked by progressive muscle weakness and atrophy. It is unique among inflammatory myopathies in its poor response to immunosuppressive therapy. IBM is characterized by both inflammatory and degenerative changes in muscle tissue. Histopathology typically reveals endomysial inflammation, rimmed vacuoles, and protein aggregates (inclusion bodies). The underlying mechanisms likely involve both autoimmune and degenerative processes. Clinically, IBM typically presents in patients over the age of 50 with slowly progressive, asymmetric weakness. It often affects the quadriceps and finger flexors, leading to difficulties in activities requiring grip or ambulation. Importantly, the disease is largely refractory to immunomodulatory treatments. Diagnosis is confirmed by muscle biopsy showing characteristic pathological features such as rimmed vacuoles and inflammatory infiltrates. The differential diagnosis includes polymyositis and other inflammatory myopathies, but IBM\u2019s distinct histopathological features and clinical course help differentiate it. There is no established effective immunomodulatory or disease\u2010modifying treatment for IBM. Management is primarily supportive, focusing on physical therapy, occupational therapy, and assistive devices to maintain function. In cases with dysphagia, targeted interventions may be necessary. While steroids and IVIG are used in other inflammatory myopathies, they have generally proven ineffective in IBM. For any female patient who is pregnant or lactating and has IBM, supportive care remains the mainstay of treatment with careful monitoring of function and nutrition. Option C (Supportive treatment) is correct because current evidence and guidelines highlight that immunosuppressive therapies like steroids (Option A) and IVIG (Option B) do not significantly alter the disease course in IBM. \u2022 IBM is the most common acquired muscle disease in older individuals and is resistant to conventional immunosuppressive therapy. \u2022 Muscle biopsy is diagnostic, showing rimmed vacuoles and inflammatory changes. \u2022 Supportive care, including physical and occupational therapy, is the mainstay of management. Recent research confirms that no immunomodulatory therapy has reliably altered the progression of IBM, and treatment guidelines emphasize supportive care. Experimental treatments continue to be investigated, but none have yet supplanted supportive strategies as the standard of care.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]